A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Hormone Receptor Positive, Her-2 Negative Advanced/metastatic Breast Cancer Patients
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) ECOG Performance Status of 0 or 1. 2) Histologic or cytologic diagnosis of metastatic breast cancer. 3) Has received no more than two lines of prior hormonal therapy for advanced nonresectable/ metastatic disease or no more than two lines of prior chemotherapy for advanced nonresectable/ metastatic disease.
You may not be eligible for this study if the following are true:
-
1) Is currently receiving an investigational agent or has received an investigational agent or used an investigational device within 28 days of study registration. 2) Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study registration. 3) Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.